Literature DB >> 9032117

Exacerbation of murine Pneumocystis carinii infection by adenoviral-mediated gene transfer of a TNF inhibitor.

J K Kolls1, D Lei, C Vazquez, G Odom, W R Summer, S Nelson, J Shellito.   

Abstract

The role of mononuclear phagocytes and their cytokine products in host defense against Pneumocystis carinii (PC) remains unclear. The cytokine tumor necrosis factor (TNF) has been proposed as critical for host defense against this pathogen. To investigate the role of this cytokine in PC infection, we treated immunocompetent mice (CD4+) or mice depleted of CD4 lymphocytes (CD4-) with a recombinant adenovirus encoding a TNF inhibitor gene (AdTNF-R). AdTNF-R treated CD4+ animals displayed delayed clearance of PC after intratracheal inoculation, whereas AdTNF-R treated CD4 animals developed more severe chronic infection. Moreover, AdTNF-R treated CD4- animals, in contrast to control CD4- mice, failed to show any interleukin-6 (IL-6) gene induction in the lung after PC challenge. The results firmly implicate TNF in host defense against PC, and support a role for TNF in orchestrating the intrapulmonary cytokine cascade in PC infection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9032117     DOI: 10.1165/ajrcmb.16.2.9032117

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  18 in total

Review 1.  Immunological features of Pneumocystis carinii infection in humans.

Authors:  P D Walzer
Journal:  Clin Diagn Lab Immunol       Date:  1999-03

2.  Increased host resistance against Pneumocystis carinii pneumonia in gammadelta T-cell-deficient mice: protective role of gamma interferon and CD8(+) T cells.

Authors:  Chad Steele; Mingquan Zheng; Erana Young; Luis Marrero; Judd E Shellito; Jay K Kolls
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

Review 3.  Update on the diagnosis and treatment of Pneumocystis pneumonia.

Authors:  Eva M Carmona; Andrew H Limper
Journal:  Ther Adv Respir Dis       Date:  2010-08-24       Impact factor: 4.031

4.  Transient neutralization of tumor necrosis factor alpha can produce a chronic fungal infection in an immunocompetent host: potential role of immature dendritic cells.

Authors:  Amy C Herring; Nicole R Falkowski; Gwo-Hsiao Chen; Rod A McDonald; Galen B Toews; Gary B Huffnagle
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

Review 5.  Current understanding of Pneumocystis immunology.

Authors:  Michelle N Kelly; Judd E Shellito
Journal:  Future Microbiol       Date:  2010-01       Impact factor: 3.165

6.  The major surface glycoprotein of Pneumocystis carinii induces release and gene expression of interleukin-8 and tumor necrosis factor alpha in monocytes.

Authors:  T L Benfield; B Lundgren; S J Levine; G Kronborg; J H Shelhamer; J D Lundgren
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

7.  Parenchymal cell TNF receptors contribute to inflammatory cell recruitment and respiratory failure in Pneumocystis carinii-induced pneumonia.

Authors:  Gloria S Pryhuber; Heidie L Huyck; Samir Bhagwat; Michael A O'Reilly; Jacob N Finkelstein; Francis Gigliotti; Terry W Wright
Journal:  J Immunol       Date:  2008-07-15       Impact factor: 5.422

8.  Steady-state effects of vitronectin and fibronectin on the binding, uptake, and degradation of Pneumocystis carinii in rat alveolar macrophages.

Authors:  J S Hoyte; J E Standing; A H Limper
Journal:  Inflammation       Date:  1997-06       Impact factor: 4.092

9.  Pulmonary hypertension can be a sequela of prior Pneumocystis pneumonia.

Authors:  Steve D Swain; Soo Han; Ann Harmsen; Katie Shampeny; Allen G Harmsen
Journal:  Am J Pathol       Date:  2007-07-19       Impact factor: 4.307

10.  Effects of surfactant protein-A on the interaction of Pneumocystis murina with its host at different stages of the infection in mice.

Authors:  Michael J Linke; Alan A Ashbaugh; Judith V Koch; Linda Levin; Reiko Tanaka; Peter D Walzer
Journal:  J Eukaryot Microbiol       Date:  2009 Jan-Feb       Impact factor: 3.346

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.